H2BFS Antibody

What is histone H2B and why is it a significant target for antibody research?

Histone H2B is one of the core histone proteins that form the nucleosome, an octameric complex around which DNA is wound. H2B is particularly notable as it is a common target of autoantibodies in both spontaneous and drug-induced systemic lupus erythematosus (SLE), with approximately 24-95% of spontaneous SLE patients and 67-100% of drug-induced lupus patients developing histone-specific antibodies . Unlike other histones, H2B uniquely accumulates relatively high levels of isoaspartic acid modifications, specifically at position 25 where Asp25 can spontaneously convert to isoaspartic acid (isoAsp) in vivo . This modification alters the protein structure and may contribute to breaking immune tolerance, making H2B an important target for understanding autoimmune mechanisms.

How do post-translational modifications of H2B affect its immunogenicity?

Post-translational modifications of H2B, particularly the isomerization of Asp25 to isoAsp, significantly alter its immunogenicity. Research demonstrates that the conversion of aspartic acid to isoaspartic acid within self-peptides renders otherwise immunologically ignored peptides highly immunogenic . Both lupus-prone mice and histone antibody-positive SLE patients develop antibodies specific to both the unmodified (Asp) and modified (isoAsp) forms of H2B peptide spanning amino acids 21-35 . The presence of an isoAsp residue at position 25 appears to be a crucial factor that makes histone H2B a target of autoimmunity, possibly explaining why autoantibodies develop against H2B in both spontaneous and drug-induced lupus . Similarly, D-isoAsp modifications at this position have been found in approximately 12% of histone H2B molecules isolated from adult mouse or dog brain .

What are the key characteristics of antibodies against modified H2B?

Antibodies against modified H2B, particularly those recognizing the D-isoAsp modification at position 25, demonstrate high specificity for their target epitopes. A polyclonal antibody developed against a synthetic peptide corresponding to amino acids 21-31 of H2B with D-isoAsp at position 25 shows strong reactivity with naturally occurring H2B from mammalian tissues, very poor reactivity with recombinant H2B (which lacks the modification), and no cross-reactivity with other histones . Quantitative assessment indicates this antibody has approximately 83-fold specificity for the modified form compared to unmodified recombinant H2B . Additionally, these antibodies can detect tissue-specific differences in H2B modification levels, with higher immunoreactivity observed in brain tissue compared to liver, thymus, and HeLa cells .

How should researchers optimize Western blotting protocols for detecting modified H2B?

When performing Western blotting to detect modified H2B, researchers should implement the following methodological approach:

• Separate proteins using SDS-PAGE on 16% Tris-Glycine gels to achieve optimal resolution of histone proteins .

• Transfer proteins to nitrocellulose membranes using a power blotter system (0.5 Amp per gel for approximately 11 minutes) .

• Block membranes for 1 hour in 5% BSA to minimize background signals .

• Incubate with primary antibody for 1.5 hours, followed by 45 minutes with HRP-conjugated secondary antibody .

• Use TBST (Tris-buffered saline with Tween) for all blocking and antibody solutions, and wash membranes 4 times for 5 minutes in TBST after each antibody incubation .

• Develop using ECL Western substrate for optimal signal detection .

For validating results, include appropriate controls such as recombinant H2B (as a modification-free control) and a loading-control antibody targeting an invariant region of H2B (e.g., an antibody against the C-terminal region around V119) .

What histone extraction protocols are most effective for preserving post-translational modifications?

To effectively preserve post-translational modifications when extracting histones for H2BFS antibody studies, researchers should:

• Use gentle extraction methods that minimize exposure to extreme pH or temperatures, which could accelerate spontaneous isomerization or racemization.

• Immediately process fresh tissue samples to prevent artificial modification accumulation during storage.

• Include protease inhibitors and phosphatase inhibitors in all buffers to prevent enzymatic degradation of histones and their modifications.

• Consider acid extraction methods (0.2N HCl or 0.4N H₂SO₄) which are effective for histone isolation while preserving many post-translational modifications .

• Avoid excessive freeze-thaw cycles of samples, as this can promote artificial isoAsp formation.

These precautions are particularly important when studying age-dependent or disease-specific accumulation of modified H2B, as improper handling could introduce artifacts that confound interpretation of results.

How can researchers differentiate between naturally occurring and artificially induced isoaspartyl modifications in H2B?

Differentiating between naturally occurring and artificially induced isoaspartyl modifications requires a multi-faceted approach:

• Use protein L-isoaspartyl methyltransferase (PIMT) enzyme assays to quantify total isoaspartyl content in histone preparations. PIMT selectively methylates L-isoAsp sites in damaged proteins .

• Compare samples from wild-type (WT) and PIMT knockout (KO) mice to establish baseline levels of natural modification accumulation versus accelerated accumulation in the absence of repair mechanisms .

• Include freshly prepared recombinant H2B as a control that initially lacks isoAsp modifications but may acquire them during experimental manipulation.

• Employ HPLC analysis coupled with mass spectrometry to directly quantify modified residues, as was done to determine that approximately 12% of H2B molecules in mouse brain contain D-Asp modifications .

• Utilize immunological approaches with highly specific antibodies against modified H2B to detect and quantify modifications across different samples.

By implementing these approaches, researchers can establish the natural occurrence patterns of isoAsp modifications and distinguish them from artifacts introduced during sample handling.

What is the relationship between TLR9 and the antibody response to modified H2B in autoimmune conditions?

The relationship between Toll-like receptor 9 (TLR9) and antibody responses to modified H2B represents an important immunological mechanism in autoimmune conditions:

• Research has demonstrated that the expression of antibodies specific to both Asp and isoAsp H2B peptides (amino acids 21-35) is dependent on TLR9 .

• TLR9 recognizes unmethylated CpG motifs in DNA and is primarily expressed in B cells and plasmacytoid dendritic cells, suggesting a mechanism by which nuclear antigens like H2B might stimulate immune responses.

• The association between H2B and DNA in nucleosomes may facilitate co-recognition of both antigens by TLR9-expressing cells, potentially explaining why anti-H2B antibodies frequently co-occur with anti-DNA antibodies in lupus.

• The 3H9 transgenic MRL lpr mouse model, which exhibits increased anti-DNA antibody production, also develops antibodies against H2B, suggesting a mechanistic link between these responses that may involve TLR9 signaling .

This TLR9 dependency highlights the potential role of innate immune mechanisms in breaking tolerance to modified self-antigens like isoAsp H2B, providing insights into the pathogenesis of autoimmune diseases like SLE.

How do tissue-specific differences in modified H2B expression impact experimental design?

Tissue-specific differences in modified H2B expression have significant implications for experimental design in research studies:

• Brain tissue exhibits higher levels of D-isoAsp-modified H2B compared to liver, thymus, and HeLa cells . Researchers should account for these differences when selecting appropriate tissue sources for their experiments.

• When comparing H2B modifications across different tissues, it is essential to implement rigorous normalization procedures, including loading controls and antibodies against unmodified regions of H2B (such as those targeting the C-terminal V119 region) .

• Nuclear extraction protocols may need to be optimized for specific tissues to ensure equivalent recovery of histone proteins, as evidenced by surprisingly low H2B levels in commercially sourced HeLa nuclear extracts .

• The enrichment of D-isoAsp H2B in brain tissue suggests potential functional relevance in neuronal gene regulation. Researchers investigating this aspect should design experiments that can distinguish between correlation and causation in tissue-specific functions.

• Age-dependent accumulation of modified H2B should be considered when designing longitudinal studies, as isoAsp formation increases with protein and tissue age.

How should researchers interpret cross-reactivity between antibodies against Asp and isoAsp forms of H2B?

Interpreting cross-reactivity between antibodies against different forms of H2B requires careful analysis:

• Studies show that both lupus-prone mice and histone antibody-positive SLE patients develop antibodies that recognize both Asp and isoAsp forms of H2B peptide 21-35 .

• This cross-reactivity appears to follow a pattern of immune response diversification, where initial responses to the modified (isoAsp) form eventually broaden to include recognition of the unmodified (Asp) form .

• Similar patterns have been observed with other post-translational modifications, such as acetylated H2B peptides, where antibody responses initially favor the modified form but later diversify to recognize both modified and unmodified variants .

• To address this challenge, researchers should employ competitive binding assays and absorption studies to determine the primary specificity of antibodies and quantify the degree of cross-reactivity.

• When using commercial or custom antibodies against modified H2B, thorough validation with both modified and unmodified peptides is essential to establish specificity profiles.

The observed cross-reactivity patterns provide valuable insights into epitope spreading mechanisms in autoimmune responses to histones, but also present challenges for precise quantification of specific modified forms.

What controls are essential for validating specificity in immunoblotting experiments with H2BFS antibodies?

Proper validation of H2BFS antibody specificity in immunoblotting experiments requires a comprehensive set of controls:

• Recombinant H2B as a negative or low-reactivity control: Purified recombinant H2B serves as an important reference point as it initially lacks the specific modifications recognized by antibodies against isoAsp or D-isoAsp forms .

• Loading control antibodies: Antibodies targeting invariant regions of H2B (such as those recognizing the C-terminal region around V119) should be used to normalize for total H2B content across samples .

• Multiple tissue sources: Comparing reactivity across different tissues known to have varying levels of the modification (e.g., brain versus liver) helps establish the dynamic range of the antibody and confirms its ability to detect biologically relevant differences .

• Cross-blot validation: Post-transfer gel staining should be performed to verify equivalent transfer efficiency across the membrane .

• Peptide competition assays: Pre-incubation of the antibody with excess modified or unmodified peptide can confirm specificity by demonstrating selective blocking of signal.

The implementation of these controls is essential for meaningful interpretation of results, particularly when comparing modification levels across different experimental conditions or disease states.

What are the potential functional implications of D-isoAsp modifications of H2B in chromatin regulation?

The presence of D-isoAsp modifications in approximately 12% of H2B molecules in mammalian brain suggests potential functional significance in chromatin regulation:

• Preliminary evidence indicates enrichment of D-isoAsp-modified H2B in active versus repressed chromatin, suggesting a potential role in gene expression regulation .

• The N-terminal domain of H2B, where Asp25 is located, extends outward from the nucleosome core and is accessible for interaction with other proteins, positioning these modifications to potentially influence chromatin-protein interactions.

• Future research should explore whether these modifications affect histone-DNA binding affinity, nucleosome stability, or recruitment of chromatin remodeling factors.

• The higher prevalence of this modification in brain tissue compared to other tissues suggests potential neuron-specific functions that warrant investigation in the context of gene expression patterns unique to neural cells .

• The relationship between D-isoAsp H2B and other histone modifications (such as methylation, acetylation, and phosphorylation) represents an important area for future investigation to understand the broader "histone code."

How might H2BFS antibodies be utilized in studying neurodegenerative conditions?

The enrichment of D-isoAsp-modified H2B in brain tissue and its potential involvement in chromatin regulation suggests several applications for H2BFS antibodies in neurodegenerative research:

• As biomarkers for protein aging and damage accumulation: Since isoAsp formation increases with protein age, H2BFS antibodies could potentially detect accelerated protein aging in neurodegenerative conditions.

• For investigating epigenetic alterations: Changes in chromatin structure and histone modifications are implicated in neurodegenerative diseases. H2BFS antibodies could help map these alterations across brain regions.

• In studying PIMT function: The protein L-isoaspartyl methyltransferase (PIMT) repairs isoAsp damage, and PIMT knockout mice develop fatal epileptic seizures at 4-6 weeks . H2BFS antibodies could help elucidate the relationship between PIMT dysfunction and neurological phenotypes.

• For chromatin immunoprecipitation (ChIP) experiments: H2BFS antibodies could potentially be used to identify genomic regions associated with modified H2B in normal versus diseased brain tissue.

• To investigate the link between protein damage and neuroinflammation: Modified histones may trigger autoimmune responses that contribute to neuroinflammation in conditions like Alzheimer's disease or multiple sclerosis.

What are the quantitative specificity profiles of antibodies against different modified forms of H2B?

Based on available research data, antibodies against modified forms of H2B demonstrate the following specificity profiles:

The polyclonal antibody against D-isoAsp H2B peptide (amino acids 21-31) shows immunoreactivity against mouse brain H2B that is 10 times that of recombinant H2B. Considering that only approximately 12% of H2B molecules in mouse brain contain D-Asp modifications, the calculated mol/mol specificity is approximately 83-fold . This antibody shows no detectable cross-reactivity with other histone proteins and is capable of distinguishing between tissue sources with different modification levels .

What differences in D-isoAsp H2B content have been documented across various tissues?

Research has documented significant tissue-specific differences in D-isoAsp H2B content:

These tissue-specific differences likely reflect variations in:

• Protein turnover rates (longer-lived proteins accumulate more modifications)

• Activity levels of repair enzymes like PIMT

• Tissue-specific chromatin states and gene expression patterns

• Age-dependent accumulation of modifications

The enrichment of D-isoAsp H2B in brain tissue is particularly noteworthy and may relate to the neurological phenotype observed in PIMT knockout mice, which develop fatal epileptic seizures at 4-6 weeks of age .